{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-282407","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2024-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.410601+00:00","generated_at":"2026-05-29T00:14:45.350970+00:00","sec_items":["1.01","3.02","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aadi Bioscience sells subsidiary for $100M, licenses ADC programs, raises $100M PIPE","bullets":["Sells wholly owned subsidiary Private Aadi to Kaken Investments for $100M; stockholder approval required.","Licenses three pre-clinical ADC programs (MUC16, PTK7, SEZ6) from WuXi Biologics; upfront $44M total.","Raises $100M via PIPE: 21.6M shares at $2.40 and 20.1M pre-funded warrants at $2.3999.","Appoints Baiteng Zhao, Ph.D. (ex-ProfoundBio CEO) to Board; he committed $3M in PIPE.","Stockholder support agreements secured for ~36% of shares; termination fee $3.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-282407","json":"https://secwatch.observer/filing/0001193125-24-282407.json","markdown":"https://secwatch.observer/filing/0001193125-24-282407.md","text":"https://secwatch.observer/filing/0001193125-24-282407.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312524282407/0001193125-24-282407-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312524282407/d891246d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T00:14:45.350970+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}